Mesa Labs net income surges 440% on quality control demand

Mesa Laboratories (NASDAQ:MLAB) reported a multi-fold increase in full-year net income, driven by robust demand in its core quality control and calibration divisions that successfully countered an ongoing stagnation in the global biopharmaceutical sector and structural weakness in China.

Revenue for the fourth fiscal quarter rose 2.6% to $63.7 million compared to the same period a year earlier.

For the full fiscal year 2026, the Lakewood, Colorado-based manufacturer generated total revenue of $249.1 million, representing a 3.4% expansion over the prior year.

Net income for the full year surged 440% to $6.7 million, bouncing back sharply from the compressed profitability recorded in fiscal 2025.

Core operating efficiency improved throughout the year.

Non-GAAP adjusted operating income, which excludes unusual and non-recurring items, climbed 11.9% to $63.5 million.

This left the company with a full-year adjusted operating margin of 25.5%, demonstrating resilient pricing power and tighter overhead management within its primary manufacturing lines.

The underlying performance revealed a stark divergence across the company’s operating segments.

The Sterilization and Disinfection Control division alongside the Calibration Solutions unit served as the primary engines of growth, buoyed by steady regulatory compliance demand from healthcare providers and pharmaceutical production facilities.

Conversely, the Biopharmaceutical Development division contracted due to a broader slowdown in capital funding for early-stage life science firms, while the Clinical Genomics business in China faced localized procurement headwinds.

Meanwhile, Mesa Labs capitalized on its enhanced profitability to fortify its balance sheet and reduce its corporate debt profile.

The company generated $39.6 million in free cash flow during fiscal 2026.

Management directed a portion of these inflows toward $14.7 million in total debt repayments, which effectively lowered the company's total net leverage ratio to 2.11 times by the close of the fiscal year, down from prior levels.